Search

Displaying results 1871 - 1880 of 10000 in total
  1. Drug

    CGC-11047

    go.drugbank.com/drugs/DB05722
    Investigational

    CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

  2. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

  3. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  4. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  5. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

    Categories: Heterocyclic Compounds, 2-Ring
  6. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  7. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS).

  8. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases.

  9. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  10. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.